{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-052729","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.610803+00:00","generated_at":"2026-05-20T10:12:13.245103+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Traws Pharma gets FDA guidance on bird flu drug tivoxavir; details stockpiling plans; cash $15.9M","bullets":["Received FDA guidance on path forward for tivoxavir marboxil (TXM) for bird flu and seasonal flu; pursuing Animal Rule for accelerated approval.","Preclinical data: single oral dose of TXM protected against lethal H5N1 (dairy-worker strain) in mice, ferrets, and non-human primates.","Phase 1 data: single 480 mg dose maintained plasma levels above EC90 for ~3 weeks; no treatment-related adverse events.","US strategic stockpile estimated at 300-600 million doses; company discussing TXM inclusion with BARDA.","Cash and equivalents of $15.9M as of March 31, 2025; expected runway into Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-052729","json":"https://secwatch.observer/filing/0001104659-25-052729.json","markdown":"https://secwatch.observer/filing/0001104659-25-052729.md","text":"https://secwatch.observer/filing/0001104659-25-052729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925052729/0001104659-25-052729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925052729/tm2516160d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:12:13.245103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}